Responses
Other content recommended for you
- Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms
- The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future
- Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment
- Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials
- Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study
- An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF)
- Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure
- Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia
- Is there benefit in implanting defibrillators in patients with severe heart failure?
- Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer–Alkmaar heart failure study